CRE Homepage About The CRE Advisory Board Newsletter Search Links Representation Comments/Ideas
Data Access
Data Quality
Regulation by Litigation
Regulation by Appropriation
Special Projects
CRE Watch List
OMB Papers
Abstracts and Reviews
Regulatory Review
Voluntary Standards Program
CRE Report Card
Public Docket Preparation
Consumer Response Service
Site Search

Enter keyword(s) to search

®: CRE Regulatory Action of the Week

CRE To Comment At FDA Nano Meeting
The Center for Regulatory Effectiveness will comment on how to regulate nano-engineered products at the Food and Drug Administrationís public meeting on the issue. The FDA meeting will occur on October 10, 2006, in Bethesda, Maryland. The pre-registration period has expired, but you may register for the meeting at the door on the day of the meeting. The FDA says it has taken measures to ensure that anyone interested will be able to attend the meeting, although the Agency does anticipate an overflow crowd.

The FDA public meeting is important because the Agency is, as a practical matter, taking the lead in determining nano regulatory policy. The FDA has also received petitions from anti-nano NGOs. The petitions demand that FDA regulate nano in the manner the NGOs like.

  • Click to read more about FDA nano public meeting